LDS/Medical Tests/Bone Morphogenetic Protein Receptor Type 1A (BMPR1A) Gene Mutation Analysis

Bone Morphogenetic Protein Receptor Type 1A (BMPR1A) Gene Mutation Analysis

Juvenile Polyposis Syndrome (JPS) is a rare autosomal dominant inherited hamartomatous polyposis syndrome with increased susceptibility to colorectal cancer caused by mutations in the SMAD4 or BMPR1A genes. The protein encoded by BMPR1A gene is a receptor belonging to the family of transmembrane serine/threonine kinases. The SMAD4 genes mediate the biological effects of the Transforming Growth Factor-β (TGF-β) superfamily located on the surface of epithelial cells. Both proteins are responsible for development of colonic mucosa.

The disease is characterized by the presence of multiple non-cancerous ‘juvenile’ polyps in the gastrointestinal (GI) tract and an increased risk for GI cancers particularly colon cancer. Although most cases occur in patients prior to age 20, the term ‘juvenile’ reflects the type of polyp not the age at which the disease manifests itself. Clinical diagnosis of JPS is typically made when one of the following criteria is met: more than five juvenile polyps in the colon or rectum; multiple juvenile polyps throughout the GI tract; or any number of juvenile polyps and a family history of gastrointestinal polyps. In addition to polyposis, 10-20% of JPS patients also have extracolonic abnormalities such as congenital heart defects, cleft lip or palate, microcephaly, and malrotations. Although a solitary juvenile polyp in the general population has very little malignant potential, patients with JPS have a 68% chance of developing gastrointestinal cancer by the age of 60. Thus, confirming a diagnosis of JPS is important for the appropriate surveillance and management of cancer patients with juvenile polyps. Genetic testing for mutation in the SMAD4 or BMPR1A genes is important in early diagnosis and management of JPS as approximately 50% of patients harbor such mutations. Identification of a heterozygous pathogenic variant in SMAD4 or BMPR1A confirms the diagnosis if clinical features are inconclusive.

  • Diagnosis of Juvenile Polyposis Syndrome
  • Confirmation of diagnosis in symptomatic individuals
  • Determination of disease status in at-risk family members
Any pathogenic variant reported in SMAD4 or BMPR1A genes will diagnose juvenile polyposis syndrome.

Negative for mutations analyzed (No reportable variants were identified)

Target sequencing for mutations, deletions and duplication using conventional sequencing or Next Generations Sequencing. Real-time Polymerase Chain Reaction (PCR) with Allele Specific Primer Extension (ASPE).

Whole blood (EDTA).

Stability

  • Ambient: 7 days
  • Refrigerated: 7-14 days
SMAD4 Germline Mutation Analysis, Lynch Syndrome, Microsatellite instability is used as an aid in the diagnosis of Hereditary Nonpolyposis Colorectal Cancer (HNPCC), Carcinoembryonic Antigen (CEA), Chromosomal analysis, Occult blood, B-RAF mutation analysis, Microsatellite Instability/HNPCC by molecular method and by IHC, Septin 9 (SEPT9), K-RAS, EGFR Mutation Detection by molecular method, p53 by molecular method and by IHC, Ki67 by IHC, and p63 by IHC.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login